Replimune

Update in progress

REPL (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies to treat cancer. Its proprietary candidates aim to activate antitumor immunity. Lead RP1 is a selectively replicating HSV-1 vector that delivers GALV-GP R(-) and GM-CSF for solid tumors. RP2 targets CTLA-4–like inhibition, and RP3 enhances T cell activation. Founded in 2015, based in Woburn, MA.

Company score

Sentiment: -0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.50; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.33; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive